Expertise in
3
conditions

Dr. Franz P. Rischard

Pulmonary Medicine
Banner-University Medical Group
535 N Wilmot Rd, Suite 101, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
Banner-University Medical Group
535 N Wilmot Rd, Suite 101, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Franz Rischard is a Pulmonary Medicine provider in Tucson, Arizona. Dr. Rischard is highly rated in 3 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Systemic Sclerosis (SSc). Dr. Rischard is currently accepting new patients.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in AZ
Hospital Affiliations
Banner - University Medical Center Tucson Campus
Banner-University Medical Center South Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

BANNER-UNIVERSITY MEDICAL GROUP
535 N Wilmot Rd, Suite 101, Tucson, AZ 85711
Other Locations
BANNER-UNIVERSITY MEDICAL GROUP
2800 E Ajo Way, Tucson, AZ 85713
BANNER-UNIVERSITY MEDICAL GROUP
3838 N Campbell Ave, Tucson, AZ 85719
BANNER-UNIVERSITY MEDICAL GROUP
1625 N Campbell Ave, Tucson, AZ 85719

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Enrollment Status: Completed
Publish Date: May 13, 2025
Intervention Type: Other, Drug
Study Drug: Sotatercept
Study Phase: Phase 3
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study
Enrollment Status: Withdrawn
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drug: Opsumit
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

79 Total Publications

Pulmonary Artery Size on CT Associates with Mean Pulmonary Artery Pressure and Mortality.
Pulmonary Artery Size on CT Associates with Mean Pulmonary Artery Pressure and Mortality.
Journal: Annals of the American Thoracic Society
Published: October 15, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Sachin Chaudhary
Pulmonary Medicine | Intensive Care Medicine
Expertise in
9
conditions
Dr. Sachin Chaudhary
Pulmonary Medicine | Intensive Care Medicine

Banner-University Medical Group

535 N Wilmot Rd, Suite 101, 
Tucson, AZ 
 (0.1 miles away)
520-694-5437
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sachin Chaudhary is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Tucson, Arizona. Dr. Chaudhary is highly rated in 9 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pneumonia, Endoscopy, and Lung Transplant. Dr. Chaudhary is currently accepting new patients.

Expertise in
21
conditions
Dr. Ubair Ahmed
Pulmonary Medicine | Intensive Care Medicine
Expertise in
21
conditions
Dr. Ubair Ahmed
Pulmonary Medicine | Intensive Care Medicine

Tmc Medical Network

1951 N Wilmot Rd, Bldg 4, 
Tucson, AZ 
 (1.2 miles away)
520-318-1114
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ubair Ahmed is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Tucson, Arizona. Dr. Ahmed is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Metastases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Bronchiectasis. Dr. Ahmed is currently accepting new patients.

Expertise in
11
conditions
Dr. Sairam N. Parthasarathy
Sleep Medicine | Pulmonary Medicine
Expertise in
11
conditions
Dr. Sairam N. Parthasarathy
Sleep Medicine | Pulmonary Medicine

Banner-University Medical Group

1625 N Campbell Ave, 
Tucson, AZ 
 (5.3 miles away)
520-694-0111
Languages Spoken:
English, Hindi, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Sairam Parthasarathy is a Sleep Medicine specialist and a Pulmonary Medicine provider in Tucson, Arizona. Dr. Parthasarathy is highly rated in 11 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Excessive Daytime Sleepiness, Central Sleep Apnea, and Drowsiness. Dr. Parthasarathy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rischard's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile